Hakai is required for stabilization of core components of the m6A mRNA methylation machinery

Bawankar, Praveen; Lence, Tina; Paolantoni, Chiara; Haussmann, Irmgard U.; Kazlauskiene, Migle; Jacob, Dominik; Heidelberger, Jan B.; Richter, Florian M.; Nallasivan, Mohanakarthik P.; Morin, Violeta; Kreim, Nastasja; Beli, Petra; Helm, Mark; Jinek, Martin; Soller, Matthias; Roignant, Jean-Yves

doi:10.1038/s41467-021-23892-5

Download PDF

Article
Open access
Published: 18 June 2021

Hakai is required for stabilization of core components of the m⁶A mRNA methylation machinery

Nature Communications volume 12, Article number: 3778 (2021) Cite this article

7430 Accesses
73 Citations
24 Altmetric
Metrics details

Subjects

Abstract

N⁶-methyladenosine (m⁶A) is the most abundant internal modification on mRNA which influences most steps of mRNA metabolism and is involved in several biological functions. The E3 ubiquitin ligase Hakai was previously found in complex with components of the m⁶A methylation machinery in plants and mammalian cells but its precise function remained to be investigated. Here we show that Hakai is a conserved component of the methyltransferase complex in Drosophila and human cells. In Drosophila, its depletion results in reduced m⁶A levels and altered m⁶A-dependent functions including sex determination. We show that its ubiquitination domain is required for dimerization and interaction with other members of the m⁶A machinery, while its catalytic activity is dispensable. Finally, we demonstrate that the loss of Hakai destabilizes several subunits of the methyltransferase complex, resulting in impaired m⁶A deposition. Our work adds functional and molecular insights into the mechanism of the m⁶A mRNA writer complex.

Role of Hakai in m6A modification pathway in Drosophila

Article Open access 12 April 2021

The Mi-2 nucleosome remodeler and the Rpd3 histone deacetylase are involved in piRNA-guided heterochromatin formation

Article Open access 04 June 2020

m6A modification of a 3′ UTR site reduces RME1 mRNA levels to promote meiosis

Article Open access 30 July 2019

Introduction

N⁶-methyladenosine (m⁶A) is one of the most abundant and well-studied mRNA modifications in eukaryotes^1,2,3,4. This modification plays a central role in almost every aspect of mRNA metabolism, and is essential for several biological processes such as cell differentiation^{1,2,3,4,5,6,7,8}, DNA repair⁹, circadian rhythm^10,11,12, neurogenesis¹³ and sex determination^14,15,16, among others. Its dysregulation in human is associated with numerous diseases, including metabolic alteration¹⁷, neuronal disorders^18,19 and various types of cancers^20,21,22. The downstream effects of m⁶A are generally mediated by YTH domain RNA-binding proteins, known as “m⁶A readers” that preferentially bind m⁶A modified RNAs and affect their fate³.

m⁶A on mRNA is deposited co-transcriptionally by a conserved multiprotein complex that can be divided into two stable sub-complexes: the heterodimer METTL3/METTL14 also known as m⁶A-METTL Complex (MAC) that contains the catalytic activity, and the m⁶A-METTL Associated Complex (MACOM) that is required for full MAC activity and includes WTAP (Fl(2)d), VIRMA (Virilizer), RBM15/RMB15B (Spenito) and ZC3H13 (Flacc)^23,24,25. More recently, another factor named HAKAI was found associated with components of MACOM in plants and human cells and required to maintain m⁶A level^26,27.

The precise function of MAC and MACOM components has been the subject of intense research over the past years. Structural studies revealed that METTL3 and METTL14 form a stable heterodimer^28,29,30 and that METTL3 is the only factor that contains the catalytic activity since METTL14 is unable to bind the methyl group donor S-Adenosylmethionine. Nevertheless, METTL14 is essential to support the interaction of the complex with its RNA targets and to enhance METTL3 activity. WTAP was shown to stabilize the interaction between METTL3 and METTL14 and to recruit the METTL3/METTL14 heterodimer into the nuclear speckles^15,31. RBM15/RBM15B is an RNA-binding protein that recognizes U-rich sequences on the mRNA and is suggested to recruit the m⁶A machinery in close proximity to these sites³². Furthermore, VIRMA was proposed to facilitate selective m⁶A installation near the stop codon and in the 3′ UTR of mRNAs through its interaction with polyadenylation cleavage factors CPSF5 and CPSF6²⁷. Lastly, four recent studies identified ZC3H13 as part of MACOM^24,27,33,34. ZC3H13 was found to stabilize the interaction between WTAP and RBM15 in mouse embryonic stem cells as well as in flies and to contribute to the localization of the writer complex to the nucleus. The only m⁶A writer component whose function is still poorly explored is HAKAI.

HAKAI, also known as CBLL1, is a RING-finger type E3 ubiquitin ligase that mediates ubiquitination and subsequent endocytosis of the E-cadherin complex, leading to cell-cell adhesion loss and increased cell motility³⁵. HAKAI can also regulate cell proliferation in an E-cadherin-independent manner by affecting the ability of the PTB-associated splicing factor to bind some of its RNA targets³⁶. During the last decades, HAKAI has been mostly studied in the context of epithelial-mesenchymal transitions and cancer progression³⁷. However, as aforementioned, it became increasingly clear that HAKAI is also a component of the m⁶A biogenesis machinery in vertebrates as well as in plants. HAKAI was identified as one of the strongest WTAP interactors in mammalian cells³⁸ and as part of an evolutionary conserved protein complex including WTAP, VIRMA and ZC3H13³⁹. Furthermore, Hakai mutant in Arabidopsis thaliana displayed mild developmental defects together with reduced m⁶A levels²⁶. Recently, we identified Hakai among the top enriched proteins in our Spenito (Nito) interactome in Drosophila S2R+ cells, suggesting its evolutionary conserved role within the m⁶A pathway²⁴.

Here we report that Hakai is a conserved member of MACOM and is essential for m⁶A deposition in flies. In line with its role in the m⁶A pathway, Hakai functions in the sex determination pathway and mediates splicing of Sex lethal. Moreover, its depletion results in altered gene expression and splicing changes that resemble the loss of other MACOM components. We find that Hakai in flies encodes short and long protein isoforms that display distinct subcellular localization. Its ubiquitin ligase domain is required for homodimerization and interaction with other MACOM components. Finally, we show that Hakai removal leads to a severe reduction of Virilizer (Vir), Fl(2)d and Flacc protein levels, indicating that Hakai is essential for maintaining the stability of MACOM components.

Results

Drosophila Hakai is a conserved MACOM subunit

We previously found Hakai among highly enriched proteins in Nito and RBM15 interactomes in Drosophila S2R+ and mouse ES cells, respectively, suggesting it is a conserved member of MACOM (Fig. 1a)²⁴. In Drosophila, Hakai can generate four protein isoforms via alternative splicing: the two short and two long isoforms differ in the extension of the C-terminal region as a result of intron retention and in the length of the second exon due to alternative 3' splice sites in the first intron (Fig. 1b). All proteins share a RING-type E3 ubiquitin ligase domain and an adjacent C2H2-like zinc finger. This region is highly conserved and was shown in mammals to be required for Hakai dimerization and formation of the so-called “Hakai phosphotyrosine-binding domain” (HYB domain) (Supplementary Fig. 1)⁴⁰. Expression of RNA isoforms was monitored during development by real-time quantitative PCR (Supplementary Fig. 2). Both short and long isoforms greatly overlapped with the m⁶A profile, showing high enrichment during early embryogenesis and in ovaries, which is consistent with the transcript distribution of the other subunits of the m⁶A methyltransferase complex^15,24. In addition, the long isoforms were particularly elevated in males, suggestive of a possible function during spermatogenesis. Intriguingly, when we examined their subcellular localization in S2R+ cells we found that the short isoform (302 aa) was present exclusively in the cytoplasm with a strong signal at the cellular periphery, in contrast to the long isoform (473 aa) that was predominantly nuclear (Fig. 1c). A similar result was obtained in BG3 cells, which are cells derived from larval brains (Supplementary Fig. 3a). Furthermore the long isoform colocalized to sites of transcription on polytene chromosomes of salivary glands (Supplementary Fig. 3b). Altogether, since m⁶A is deposited co-transcriptionally, these results suggest that only the long isoform may be relevant with regards to m⁶A biogenesis.

**Fig. 1: Hakai interacts with MACOM components.**

To address if Hakai indeed interacts with MACOM components in Drosophila, we cloned Hakai cDNA encoding long (473 residues) isoform in a Myc-GFP-tagged expression vector and transfected the construct in Drosophila S2R+ cells to carry out Myc pull-down assay followed by mass spectrometry analysis. We found that the tagged Hakai was able to immunoprecipitate all MACOM components, even though the interaction with Nito was just below the cutoff (Fig. 1d, Supplementary Data 1). Furthermore, Mettl3 and Mettl14 were absent from the precipitated proteins, confirming our previous findings that the interaction between MAC and MACOM is either weak or transient.

To confirm these results, we performed co-immunoprecipitation assays in S2R+ cells. We found that Hakai can interact with other MACOM components, irrespective of the presence of RNA (Fig. 1e, f). Further confirmation of the interaction between Hakai and Fl(2)d/Nito was obtained via yeast-two-hybrid (Y2H) assay (Fig. 1g). However, interaction between Hakai and Flacc was not detected in this assay and Vir could not be successfully expressed in yeast, probably due to its large size. Furthermore, in agreement with the human HAKAI structure⁴⁰, we observed that the Hakai fly orthologue could homodimerise, as well as Fl(2)d and Nito, which was not reported previously (Supplementary Fig. 4a, b).

Altogether our data indicate that Hakai is a component of the m⁶A machinery in flies, that it interacts with MACOM components, and that several subunits within this complex likely exist in more than one copy.

Vir functions as a scaffold for MACOM component interaction

To gain better mechanistic insights of Hakai within MACOM, we precisely mapped the intermolecular interactions between the different components of the complex. To do so, we performed co-immunoprecipitation experiments in the presence of RNase A using full length as well as fragments of MACOM subunits in different combinations (Fig. 2a). Results from these experiments revealed that Hakai N-terminal region (residues 1-295, common to both isoforms) interacts with the N-terminal region of Vir (residues 1–130) (Fig. 2b, c), while the middle region and C-terminus of Fl(2)d (residues 125-536) binds Vir C-terminal (residues 1501–1854) (Fig. 2d, e). The same region of Fl(2)d was also required for homodimerisation (Supplementary Fig. 4a). These data suggest that Vir may mediate the interaction between Fl(2)d and Hakai. To address this possibility, we tested whether Hakai and Fl(2)d still interact in the absence of Vir. The co-immunoprecipitation assay revealed that the interaction was strongly compromised upon vir KD (Fig. 2f and Supplementary Fig. 5a). Similarly, the interaction between Hakai and Nito was dramatically reduced (Supplementary Fig. 5a, b). In contrast, the lack of Hakai did not interfere with the association of Fl(2)d with Nito or Vir (Supplementary Fig. 5c–e). Therefore these results suggest that Vir likely stabilize the interaction between Fl(2)d, Hakai and Nito (Fig. 2g).

**Fig. 2: Virilizer acts as a scaffold between Hakai and Fl(2)d.**

We next explored whether these interactions are conserved in the human MACOM. To this end, we overexpressed several human MACOM subunits (Supplementary Fig. 6a) in HEK293T cells and performed co-imunoprecipitation experiments in the presence of RNase A. We found that the interaction between HAKAI and the N-terminal domain of VIRMA (residues 1–130) is conserved between Drosophila (Fig. 2b, c) and humans (Supplementary Fig. 6b, c). We further showed that a region of HAKAI spanning residues 87–105, which is not present in the previously determined structure⁴⁰, is critical for this interaction (Supplementary Fig. 6c, lanes 11–12). Similarly, the predicted structured region of the Fl(2)d homologue WTAP (residues 1–249) co-imunoprecipitated with VIRMA (Supplementary Fig. 6d). In case of human VIRMA, we identified two distinct interaction domains. On one hand VIRMA interacts with WTAP through its C-terminal domain (residues 1575–1812) (Supplementary Fig. 6e), as shown for Drosophila. We also identified a second WTAP interacting site in the central region of the protein spanning residues 335-1130 (Supplementary Fig. 6e, lane 14). Interestingly, truncating this region further from either side abolished the interaction (Supplementary Fig. 6e, lanes 15–16), suggesting that WTAP binding involves multiple interaction sites or that the truncations disrupt the VIRMA protein fold. Altogether, these results demonstrate that VIRMA serves as an interaction platform for the assembly of HAKAI and WTAP into the MACOM complex in both Drosophila and humans (Fig. 2g, h).

Hakai is required for mRNA m⁶A methylation and alternative splicing of Sex lethal (Sxl)

A key role for m⁶A in Drosophila has been shown in alternative splicing of Sex lethal (Sxl), where it is required for autoregulation in females⁴¹. In females, Sxl binds to either side of an alternative exon containing a stop codon and blocks the splice sites to skip this exon, which is only included in males. In addition, Sxl also prevents expression of the dosage compensation factor msl-2, which is expressed only in males to upregulate transcription from the single X chromosome twofold. Loss of m⁶A interferes with sexual differentiation in females and increases female lethality due to aberrant dosage compensation^14,15,16. Hence, we wondered whether loss of Hakai is also required for mRNA m⁶A methylation and interferes with Drosophila sex determination and dosage compensation.

We obtained a previously characterized imprecise transposon excision line in the Hakai gene⁴². This Hakai¹ allele lacks the coding region covering the N-terminus and the RING-finger domain, and is considered to be a null loss of function (Fig. 3a). In addition, we used the CRISPR/Cas9 approach to generate Hakai, which encodes an early truncated product (first 57aa). When we crossed Hakai¹ to either of the two deficiency alleles (Df(2L)Exel8041 or Df(2L)Exel6044) to normalize genetic background effects, we found that the mutants died in the pupal stage (n = 240). The m⁶A level of Hakai¹/Df(2L)Exel8041 pupae was reduced compared to the control (Fig. 3b–d), but not completely absent as in Mettl3^null mutants¹⁴.

**Fig. 3: Hakai is required for m⁶A methylation and sex determination by regulating *Sex-lethal* alternative splicing.**

To test whether Hakai is required for Sxl autoregulation, we made use of a genetically sensitized background based on reduced Sxl levels by removal of one copy of daughterless (da), which is involved in Sxl transcription, and one copy of Sxl required for Sxl autoregulation. In the progeny of a cross between da^Df/+; Mettl3^null/+ females and Sxl^7B0 null males, most females died (Fig. 3e). Likewise, also removal of one copy of Hakai killed females (Fig. 3e).

Furthermore, when we crossed Hakai/CyO females, which harbours an early stop codon, to Df(2L)Exel8041/CyO males to normalize genetic background, we observed strong female lethality compared to CyO balancer-carrying control animals (149 females and 144 males, Fig. 3f). Although the two females we obtained did not show sexual transformation, all male flies were flightless (n = 44), as observed for Mettl3^null and Mettl14^null mutants^14,15,16.

To further confirm the involvement of Hakai in Sxl alternative splicing we made use of the female-lethal vir^2F allele¹⁴. We found that removal of one copy of Hakai restored female viability of vir^2F/Df(2R)BSC778 females by correcting Sxl alternative splicing (Fig. 3g), as shown previously for other components of the methyltransferase complex^14,24.

Lastly, to demonstrate a role for Hakai in the sexual differentiation of Drosophila females we made use of the vir^2F/vir^ts genetically sensitized background, which occasionally shows patches of darkly pigmented male tissue in abdominal segments 5 and 6 in these females (Fig. 3j–l). Strikingly, removal of one copy of Hakai led to male pigmentation in the vast majority of these females (Fig. 3h, m) and a switch of Sxl alternative splicing to the male mode, including the otherwise skipped male exon (Fig. 3i, lane 5). Some females also displayed intersexual development of genitals (Fig. 3n). Intriguingly, loss of Hakai in the vir^2F/vir^ts genetically sensitized background revealed tissue-specificity in Sxl regulation as alternative splicing in the front part of females (head and thorax) was not altered, and also these females did not display male sex combs (Fig. 3h), suggesting the m⁶A pathways main function could be to guarantee robust Sxl alternative splicing across different tissues.

Hakai regulates the m⁶A pathway in Drosophila

To further corroborate Hakai as a genuine m⁶A writer in Drosophila, we depleted its product in S2R+ cells and compared its effect with the KD of other m⁶A pathway components. In agreement with Hakai being part of the m⁶A writer complex, its loss led to a significant reduction of m⁶A levels on mRNA as measured by mass spectrometry (Fig. 4a). However, this reduction (32%) was not as pronounced as the m⁶A reduction observed upon depletion of the Mettl3/Mettl14 heterodimer (59%), which is consistent with the results obtained by TLC from Hakai¹/Df mutant pupae (Fig. 3c, d). We next investigated its involvement in the regulation of m⁶A-dependent splicing events. We previously reported changes in the splicing pattern of several transcripts upon KD of individual m⁶A writers^15,24. Splicing isoform quantification by RT-qPCR of two of the affected transcripts, fl(2)d and Hairless, resulted in a comparable isoform shift in Hakai KD and Mettl3/Mettl14 KD in S2R+ cells (Fig. 4b). On a transcriptome-wide level, depletion of Hakai resulted in changes in gene expression and splicing that substantially overlap with changes occurring upon KD of other components of the m⁶A machinery (Fig. 4c; Supplementary Fig. 7). In particular, Hakai KD led to an increase of both alternative 5′ splice site usage and intron retention, consistent with our previous findings on the individual MACOM component depletion (Fig. 4d²⁴). Note that depletion of MACOM components has a stronger impact on gene expression and splicing compared to the loss of MAC components. This is consistent with previous genetic data showing that Mettl3 and Mettl14 are dispensable for fly viability while MACOM subunits are not^14,15,16, supporting additional function(s) for MACOM components. Altogether, these results demonstrate that Hakai is a bona fide component of MACOM and is required for m⁶A biogenesis and function.

**Fig. 4: Hakai regulates m⁶A levels and m⁶A-dependent splicing events.**

The Hakai ubiquitination domain but not its activity is required for maintaining MACOM integrity

We next sought to address the molecular role of Hakai within MACOM. As Hakai is a well-studied E3 ubiquitin ligase in mammals, we wondered whether its ubiquitination activity plays any role within the m⁶A pathway. To address this possibility, we generated constructs expressing either the wild-type Hakai cDNA (Hakai^WT) or a cDNA containing point mutations in the RING domain (Hakai^ΔRING) that should abolish ubiquitination activity (see “Methods”). We then performed rescue experiments in our Hakai mutant flies and found that while the wild-type form was able to rescue the lethality, the mutated version failed to do so. This indicates that the RING domain is required for fly viability.

We therefore wondered if Hakai might regulate m⁶A levels by ubiquitination of MACOM components. To investigate this possibility we examined our previous ubiquitylome datasets from Drosophila S2 cells and found that Fl(2)d and Nito were among the ubiquitinated proteins⁴³. Thus, we cloned both proteins in a GFP-tag containing vector and expressed them in control and Hakai depleted S2R+ cells to monitor their ubiquitination. We immunoprecipitated both proteins under stringent 8 M Urea conditions and while we could not detect any ubiquitination signal for Nito, Fl(2)d appeared to be polyubiquitinated, as shown by a strong shift in molecular weight by more than 100 kDa (Supplementary Fig. 8a). Using mass spectrometry analysis, we could map two of the four previously identified sites (K236 and K245) in Fl(2)d (Supplementary Data 2), residing in the region required for homodimerization and interaction with Vir (Fig. 2e, Supplementary Fig. 4a). We noticed that Fl(2)d ubiquitination was reduced in the Hakai KD condition; however, the overall level of immunoprecipitated Fl(2)d was also diminished. We therefore repeated this experiment in control condition and after proteasome inhibition to prevent protein degradation. This experiment confirmed our previous observations; Fl(2)d was ubiquitinated and its protein intensity was strongly reduced upon Hakai KD. However, upon proteasome inhibition, levels of Fl(2)d as well as its ubiquitination remained unchanged despite efficient Hakai depletion (Supplementary Fig. 8b). This indicates that Hakai is not responsible for Fl(2)d ubiquitination, but is required for its stability.

To get better insight into the function of Hakai as an E3 ubiquitin ligase and find other putative targets, we next performed a ubiquitylome analysis in S2R+ cells in control versus Hakai KD condition. Cells isotopically labelled with heavy amino acids were depleted for Hakai and cells isotopically labelled with light amino acids served as a control in the forward experiment. A vice versa depletion was performed in the reverse experiment (Supplementary Fig. 8c). Proteins were digested with endo-proteinase Lys-C and peptides were further enriched with di-glycine-lysine remnant-recognizing antibody to identify ubiquitination sites via LC-MS/MS. We found over 3000 ubiquitination sites, but unexpectedly not a single site was reproducibly reduced in response to Hakai depletion and only one site in SesB was 1.5-fold increased (Fig. 5a, Supplementary Data 3). Therefore, this experiment suggests that Hakai does not act as an E3 ubiquitin ligase in Drosophila S2R+ cells. Alternatively, it is possible that its ubiquitination activity depends on specific external stimuli or that we have not quantified the ubiquitination sites that are regulated by Hakai due to the limited depth of the analysis.

**Fig. 5: Hakai RING domain is required for interaction with MACOM components.**

We wondered what could explain the apparent discrepancy between our in vivo results, indicating the importance of the Hakai RING domain and the data obtained from S2R+ cells. Previous crystal structure in mammals showed that the RING domain is required for HAKAI dimerization⁴⁰. One possibility could be that the point mutations we generated in the RING domain alter the ability of Hakai to dimerize and perhaps to interact with other MACOM components. To test this idea, we performed co-immunoprecipitation experiments by co-transfecting S2R+ cells with Myc-GFP-tagged Hakai either wild type or mutated in the RING domain and other components of MACOM, including Hakai itself. While WT Myc-GFP-Hakai strongly immunoprecipitated HA-Hakai, the RING mutant failed to do so, indicating that, like in mammals, the RING domain is required for Hakai homodimerization (Fig. 5b). More importantly, interactions with Fl(2)d and Vir were also strongly compromised (Fig. 5c, d). We interpret this result as an indication that Hakai dimerization is likely required for its association with other MACOM components.

Hakai is required for stabilization of MACOM components

Our results so far indicate that Hakai does not possess any ubiquitin activity towards MACOM components, and that it also does not serve as a scaffold to permit the assembly of these components. Nevertheless, as mentioned above, we found that Hakai depletion strongly destabilized Fl(2)d protein levels. In addition, we noticed in our co-immunoprecipitation experiments that the level of protein input for Fl(2)d and Vir was consistently reduced upon Hakai KD (Supplementary Fig. 5c, d), suggesting that Hakai may be required to stabilize these subunits. For this reason, we had to transfect twice the amount of these components to have comparable input level and therefore interpretable co-immunoprecipitation data. To confirm these observations, we took an unbiased approach by performing a global proteome analysis in S2R+ cells following Hakai depletion. As expected, Hakai levels were strongly reduced, indicating a successful KD (Fig. 6a). More strikingly, we identified seven additional proteins that were strongly down regulated, and among them three MACOM components: Fl(2)d, Flacc and Vir (Supplementary Data 4). The extent of downregulation for Vir was similar as for Hakai, indicating that Hakai loss has a particularly strong impact on Vir stability. In contrast, we did not detect any substantial changes in the protein levels of Nito, Mettl3 and Mettl14. We could confirm by western blot the specific reduction of the Fl(2)d level (Fig. 6b, c and Supplementary Fig. 9d). However, immunofluorescence assay showed that its nuclear localization was not affected (Supplementary Fig. 8d).

**Fig. 6: Hakai regulates the stability of other MACOM components.**

To examine whether the loss of Fl(2)d or Vir also impacts the stability of other m⁶A writer components, we repeated the S2R+ proteome analysis after depletion of these proteins. We found that Fl(2)d protein levels were significantly reduced upon vir KD and vice versa (Supplementary Fig. 9a-c). Similarly, as shown upon Hakai depletion, Flacc level was also decreased. However, in both cases, levels of Hakai and Nito were not affected. This was also confirmed by western blot (Fig. 6d and Supplementary Fig. 9e). Collectively, these results indicate that Hakai functions in stabilizing three MACOM components and this is likely the reason why m⁶A levels are reduced upon its depletion.

The role of Hakai in MACOM component stabilization is conserved in human

Given the high conservation of Hakai with its human ortholog and its interaction with Vir, we wondered if HAKAI function within MACOM is conserved in humans. To this end, we depleted human HAKAI and VIRMA in HeLa and U2OS cells and monitored the protein levels. We observed that the loss of VIRMA had no effect on HAKAI level (Fig. 6e), as also shown with the Drosophila homologues. In contrast, depletion of HAKAI strongly reduced VIRMA levels but not the levels of RBM15, the human ortholog of Nito. Altogether, these findings indicate that the role of HAKAI within MACOM is conserved in humans and that Hakai is indispensable for maintaining the functionality of m⁶A writer by ensuring the stability of MACOM components (Fig. 7).

**Fig. 7: Model showing the composition of the m⁶A methyltransferase complex in fly and human and the impact of Hakai on MACOM integrity.**

Discussion

We recently showed that two conserved sub-complexes, MAC and MACOM interact to deposit m⁶A on mRNA in flies and mice²⁴. While the structure of the catalytic MAC, which consists of the heterodimer METTL3 and METTL14, has been thoroughly characterized^28,29,30, our knowledge of MACOM is limited. In particular, the full composition, assembly and exact function of each subunit have remained unclear. Our study identifies Hakai as an integral component of MACOM in Drosophila and human cells. In line with this function, we show that Hakai interacts with Vir and other MACOM components, and its depletion reduced m⁶A levels and led to altered gene expression, resembling loss of other MACOM subunits. Furthermore, flies lacking Hakai are lethal and display aberrant splicing of Sex lethal, consistent with the role of MACOM in sex determination and dosage compensation pathways. The few individuals that escape lethality are flightless, as shown earlier in other mutants of the m⁶A pathway. Mechanistically, we found that Hakai is required to stabilize several MACOM components, likely explaining its requirement for m⁶A deposition.

The question that arises is whether all MACOM components have now been identified. We and others have validated five factors, which include Fl(2)d, Vir, Flacc, Nito and Hakai (this study and^{14,15,16,24,33}). Earlier biochemical studies estimated a molecular weight of 875 kDa for the large form of the human methyltransferase complex⁴⁴. The calculated total molecular weight of the combined five factors corresponds to 600 kDa, which suggests that the complex contains additional factors or multiple copies of the known factors. Our data show that Hakai, Fl(2)d and Nito have the ability to self-interact (Supplementary Fig. 4). If we assume that these three factors are present as dimers, the total weight reaches up to 868 kDa, which would be consistent with the predicted mass of MACOM. Nevertheless, additional biochemical and structural characterization will be required to confirm the exact identity and stoichiometry of the different complex components.

While Hakai is undoubtedly a core component of the complex, it is surprising that its gene inactivation results in milder phenotypes in comparison to the inactivation of other MACOM components. Indeed, the few females that escaped developmental lethality in the Hakai loss-of-function mutant did not display male sex combs and this phenotype was also not observed in a sensitized background with reduced Hakai dosage. However, the females did show male pigmentation on their abdomen, indicating tissue-specific alteration of sex determination. These milder defects are consistent with our quantification of the m⁶A level in the Hakai mutant (Fig. 3), which appeared reduced but not completely absent, as observed in the Mettl3 mutant¹⁴. Also, Sxl splicing showed tissue-specific alterations, indicative of local requirement for this factor. These results are consistent with a previous study in Arabidopsis showing less pronounced impact of Hakai on the m⁶A levels as well as on organismal development²⁶. This apparent discrepancy may be explained by the function we uncovered in this work. Our data show that upon depletion of Hakai the level of some of the other MACOM components is reduced but not completely lost (Fig. 6), which suggest that the remaining MACOM could still support methylation. In this case, tissue-specific requirement may be mediated through differential expression of factors that may impact on this residual interaction and could determine tissue-specific levels of m⁶A. Additional work would be required to test this hypothesis.

In vertebrates, Hakai was shown to ubiquitinate E-cadherin and promote its degradation³⁵. In contrast, our data from Drosophila cells provide no evidence for ubiquitination activity towards MACOM components or any other proteins. Instead, our work strongly suggest that Hakai is required for the stability of three MACOM components, Vir, Fl(2)d and Flacc, independently of its enzymatic activity. The question that remains is how does Hakai exert this function. It was previously shown that the so-called “orphan proteins” are unstable and get degraded if their protein partners that constitute a common complex are absent. Destabilization can be triggered due to aberrant protein folding, altered localization or because of exposure of normally protected protein binding interfaces⁴⁵. It is therefore possible that Hakai stabilizes other MACOM components via one of these mechanisms. If this model is true, other components of the complex are also expected to stabilize each other. Indeed, we found that protein levels of Vir, Fl(2)d and Flacc were also strongly reduced upon loss of Vir or Fl(2)d (Fig. 6). Interestingly, in mES cells a strong reduction of Wtap levels was previously reported upon loss of Virma²⁷ and a strong destablization of Zc3h13 was observed upon depletion of Virma, Wtap or Hakai³⁴, suggesting a conserved mechanism for Hakai-Vir-Fl(2)d-Flacc stabilization between flies and mice. We further demonstrated that protein levels of Hakai and Nito are unperturbed upon depletion of other MACOM components, suggesting that Hakai and Nito might function in additional processes not linked to MACOM or m⁶A-deposition. This is in agreement with observations that Hakai also localizes in the cytoplasm, and with a study that found Nito (RBM15) in an evolutionary conserved protein complex with proteins unrelated to remaining MACOM components³⁹.

Given our insights from the current study, we propose the following model of MACOM assembly: (i) Fl(2)d-Vir-Hakai form a minimal protein unit that is required for the assembly and functionality of the remaining methyltransferase complex. (ii) Stability of Fl(2)d and Vir depends on each other and Hakai, but is largely independent of Flacc and Nito. (iii) Fl(2)d-Vir-Hakai can interact with MAC, however, this is not sufficient for m⁶A deposition. (iv) Joining of Flacc and Nito is essential for the formation of a complete MACOM complex that can bind and methylate its targets together with MAC.

In conclusion, our work revealed the requirement of Hakai for m⁶A deposition in Drosophila. The apparent dependency of Fl(2)d, Vir and Flacc for each other’s stability might be an important mechanism that maintains an equilibrium of protein stoichiometry for a complete complex assembly in order to prevent aberrant interactions of orphan subunits and unwanted m⁶A installation. Given the critical role of m⁶A in multiple physiological processes, it will be important to address whether perturbation of this equilibrium, for instance, by single nucleotide polymorphism, may impact the development or severity of pathological conditions.

Methods

Drosophila stocks and genetics

Drosophila melanogaster CantonS was used as the wild-type control. All Hakai alleles and corresponding chromosomal deficiencies (Df(2L)Exel8041 and Df(2L)Exel6044) were re-balanced with a CyO balancer that is marked by actinGFP and w+ to determine the lethal stage and collect homozygous Hakai null animals. Sexing at the larval stage was done by monitoring the presence of the male gonad.

The P{VSH330548)attP40 Hakai RNAi line was obtained from Vienna Drosophila Resource Center). Hakai was generated using the CRISPR-Cas9 system following the previously described procedure⁴⁶. Two independent guide RNAs were designed using the gRNA design tool: www.crisprflydesign.org (Supplementary Data 5). Oligonucleotides were annealed and cloned into pBFv-U6.2 vector (National Institute of Genetics, Japan). The vector was injected into embryos of TBX-0002 (y1, v1, P{nos-phiC31\int.NLS}X; attP40 (II)) flies by Bestgene Inc. Flies were crossed with TBX-0008 (y2 cho2 v1/Yhs-hid; Sp/CyO) flies to identify positive recombinant flies by eye colour marker (Vermillon). Males were further crossed with CAS-0001 (y2, cho2, v1; attP40(nos-Cas9)/CyO) females. Males carrying nos-Cas9 and U6-gRNA transgenes were screened for the expected deletion using oligos in Supplementary Data 5.

For genetic interaction studies, we used Mettl3^null and vir alleles as described²⁴. The da deficiency was Df(2L)BSC209.

Cloning

The plasmids used for immunohistochemistry and co-immunoprecipitation assays (shown in Fig. 1d, e) were constructed by cloning the corresponding cDNA in the pAC vector with the N-terminal Myc- tag (Hakai short and Hakai long) or N-terminal Myc-GFP tag (Fl(2)d and Nito)¹⁵. For plasmids with the C-terminal HA tag, the corresponding cDNA was cloned in the Gateway-based vector (pPWH) obtained from Drosophila Genomics Resource Center (DGRC) at Indiana University as described in ref. ¹⁵. To generate the RING mutant construct the corresponding mutations were introduced: histidine at position 183 was replaced by alanine in combination with cysteine to alanine conversion for the residues 165, 168, 181, 186, 189, 198 and 201. The stability of the protein was not affected by these mutations. Hakai long and Ring mutant cDNA were cloned in the pUAST-eGFP-attB vector between BamH1 and Xba1 sites and the constructs were sent to BestGene for injections.

Myc-GFP construct was generated by cloning Myc tag in directional cloning within the Kpn1 restriction site in pAc5.1B-EGFP-V5-His vector. This construct also has V5-His in frame after EGFP. This construct was used as negative control for the experiment. Then all cDNAs were cloned in this vector for the subsequent experiments. For HA-tagged constructs all the cDNAs were cloned in pAc5.1B-lambdaN-HA vector in suitable restriction sites.

Cell culture, RNA interference and transfection

Drosophila S2R+ cells were grown in Schneider’s medium (Gibco) supplemented with 10% FBS (Sigma) and 1% penicillin–streptomycin (Sigma). For RNA interference (RNAi) experiments, PCR templates for the dsRNA were prepared using T7 megascript Kit (NEB). dsRNA against bacterial β-galactosidase gene (lacZ) was used as a control for all RNA interference (RNAi) experiments. S2R+ cells were seeded at the density of 10⁶ cells/ml in serum-free medium and 7.5 μg of dsRNA was added to 10⁶ cells. After 6 h of cell starvation, serum supplemented medium was added to the cells. dsRNA treatment was repeated after 48 and 96 h and cells were collected 24 h after the last treatment. Effectene (Qiagen) was used to transfect vector constructs in all overexpression experiments following the manufacturer’s protocol.

For knockdown in HeLa and U2OS cells, siRNAs against VIRMA (catalogue no. s24832), HAKAI (catalogue no. s36537) as well as negative control siRNA were purchased from Ambion. siRNAs were transfected with Lipofectamine 2000 RNAi MAX (Invitrogen) according to the manufacturer’s protocol.

Drosophila cell lines

Drosophila S2R+ cells were embryonic-derived cells obtained from the DGRC (at Indiana University; FlyBase accession FBtc0000150). Drosophila BG3 cells were derived from larval nervous system and also obtained from the DGRC(at Indiana University; FlyBase accession FBtc0000068). Both cell lines were tested for Mycoplasma infection by RNA-seq experiments.

Drosophila staging

The staging experiment was performed as described previously¹⁵ using D. melanogaster w1118 flies. A total of three independent samples was collected for each Drosophila stage as well as for heads and ovaries. Samples from the staging experiment were used for RNA extraction to analyze m⁶A abundance in mRNA and expression levels of different transcripts during Drosophila development.

RNA isolation and mRNA purification

Total RNA from S2R+ cells was isolated using Trizol reagent (Invitrogen), and DNA was removed with DNase I treatment (New England Biolabs). Fly heads from 3- to 5-day-old flies were separated and homogenized in Trizol prior to RNA isolation. mRNA was isolated by two rounds of purification with Dynabeads Oligo d(T)25 (New England Biolabs).

RT-PCR

cDNA was prepared using M-MLV reverse transcriptase (Promega). Transcript levels were quantified using Power SYBR Green PCR master mix (Invitrogen) and the oligonucleotides indicated in Supplementary Data 5.

For Sxl quantification, Total RNA was extracted using Tri-reagent (SIGMA) and reverse transcription was done with Superscript II (Invitrogen) according to the manufacturer’s instructions using an oligodT17V primer. PCR for Sxl was done for 40 cycles with 1 μl of cDNA with primers Sxl F2 (ATGTACGGCAACAATAATCCGGGTAG) and Sxl R2 (CATTGTAACCACGACGCGACGATG). Experiments included three biological replicates.

LC–MS/MS analysis of m⁶A levels

mRNA samples for LC-MS/MS analysis were prepared as mentioned above. Three hundred nanograms of purified mRNA was digested with 0.3 U Nuclease P1 from Penicillium citrinum (Sigma-Aldrich, Steinheim, Germany) and 0.1 U Snake venom phosphodiesterase from Crotalus adamanteus (Worthington, Lakewood, USA) in 25 mM ammonium acetate, pH 5, supplemented with 20 µM zinc chloride for 2 h at 37 °C. Remaining phosphates were removed by 1 U FastAP (Thermo Scientific, St Leon-Roth, Germany) in the manufacturer-supplied buffer, in a 1 h incubation at 37 °C. The resulting nucleoside mix was then spiked with 13C stable isotope labelled nucleoside mix from Saccharomyces cerevisiae RNA as an internal standard (SIL-IS) to a final concentration of 4 ng/µl for the sample RNA and 2 ng/µl for the SIL-IS. For the analysis, 10 µl of the before mentioned mixture were injected into the LC–MS/MS machine. Generation of technical triplicates was obligatory. All mRNA samples were analyzed in biological triplicates. LC separation was performed on an Agilent 1200 series instrument, using 5 mM ammonium acetate buffer as solvent A and acetonitrile as buffer B. Each run started with 100% buffer A, which was decreased to 92% within 10 min Solvent A was further reduced to 60% within another 10 min Until minute 23 of the run, solvent A was increased to 100% again and kept at 100% for 7 min to re-equilibrate the column (Synergi Fusion, 4 µM particle size, 80 Å pore size, 250 × 2.0 mm, Phenomenex, Aschaffenburg, Germany). The ultraviolet signal at 254 nm was recorded via a DAD detector to monitor the main nucleosides. MS/MS was then conducted on the coupled Agilent 6460 Triple Quadrupole (QQQ) mass spectrometer equipped with an Agilent JetStream ESI source which was set to the following parameters: gas temperature, 350 °C; gas flow, 8 l/min; nebulizer pressure, 50 psi; sheath gas temperature, 350 °C; sheath gas flow, 12 l/min; and capillary voltage, 3,000 V. To analyze the mass transitions of the unlabelled m⁶A and all 13C m⁶A simultaneously, we used the dynamic multiple reaction monitoring mode.

Analysis of m⁶A methylation by TLC

Total RNA was extracted with Trizol (Invitrogen) and PolyA mRNA from oligo dT selection was prepared according to the manufacturer (Promega). For each sample, 50 ng of polyA mRNA was cut with RNAse T1 (1000U, Fermentas) and 5′-endlabeled using 10 U of T4 PNK (NEB) and 0.5 µl [γ-³²P] ATP (6000 Ci/mmol, 25 µM; Perkin-Elmer) in T4 PNK buffer for 2 h. The labelled RNA was precipitated, washed twice with 70% ethanol, resuspended in 10 µl of 50 mM sodium acetate buffer (pH 5.5) and digested with P1 nuclease (SIGMA) for 1 h at 37 °C. Two microliters of each sample was loaded on cellulose F TLC plates (20 × 20 cm; Merck) and run in a solvent system of isobutyric acid:0.5 M NH₄OH (5:3, v/v), as first dimension, and isopropanol:HCl:water (70:15:15, v/v/v), as the second dimension. TLCs were repeated from biological replicates. The identity of the nucleotide spots was determined as described¹⁴. For the quantification of spot intensities on TLCs, a storage phosphor screen (K-Screen; Kodak) and Molecular Imager FX in combination with QuantityOne software (BioRad) were used.

Immunostaining

For staining of Drosophila S2R+ and BG3 cells, cells were transferred to the eight-well chambers (Ibidi) at a density of 2 × 10⁵ cells per well. After 30 min, cells were washed with 1× DPBS (Gibco), fixed with 4% formaldehyde for 10 min, and permeabilized with PBST (0.2% Triton X-100 in PBS) for 15 min. Cells were incubated with mouse anti-Myc (1:2000, Enzo, 9E10) or mouse anti-Flag (1:1000) in PBST supplemented with 10% donkey serum overnight at 4 °C. Cells were washed three times for 15 min in PBST and then incubated with secondary antibody and 1× DAPI solution in PBST supplemented with 10% donkey serum for 2 h at 4 °C. After three 15-min washes in PBST, cells were imaged with a Zeiss LSM 710 confocal microscope using a 63× oil immersion objective.

For polytene chromosome staining, the long Hakai isoform was expressed in salivary glands with C155-GAL4 as described¹⁴. Briefly, larvae were grown at 18 °C under non-crowded conditions. Salivary glands were dissected in PBS containing 4% formaldehyde and 1% TritonX100, and fixed for 5 min, and then for another 2 min in 50% acetic acid containing 4% formaldehyde, before placing them in lactoacetic acid (lactic acid:water:acetic acid, 1:2:3). Chromosomes were then spread under a siliconized cover slip and the cover slip removed after freezing. Chromosome were blocked in PBT containing 0.2% BSA and 5% goat serum and sequentially incubated with primary antibodies (mouse anti-Pol II H5 IgM, 1:1000, Abcam, and rat anti-HA MAb 3F10, 1:50, Roche) followed by incubation with Alexa488- and/or Alexa647-coupled secondary antibodies (Molecular Probes) including DAPI (1 µg/ml, Sigma).

Co-immunoprecipitation assay and western blot analysis of the Drosophila MACOM subunits

For the co-immunoprecipitation assays shown in Fig. 1e, f, different combinations of vectors with the indicated tags were co-transfected in S2R+ cells. Forty-eight hours after transfection, cells were collected, washed with DPBS, and pelleted by centrifugation at 400 × g for 10 min The cell pellet was lysed in 1 ml of lysis buffer (50 mM Tris-HCl at pH 7.4, 150 mM NaCl, 0.05% NP-40) supplemented with protease inhibitors and rotated head over tail for 15 min at 4 °C. Nuclei were collected by centrifugation at 1000 × g for 10 min at 4 °C, resuspended in 300 μL of lysis buffer, and sonicated with five cycles of 30 s on and 30 s off at the low power setting. Cytoplasmic and nuclear fractions were joined and centrifuged at 18,000 × g for 10 min at 4 °C to remove the remaining cell debris. Protein concentrations were determined using Bradford reagent (Bio-Rad). For immunoprecipitation, 2 mg of proteins was incubated with 2 μg of anti-Myc antibody coupled to protein A/G magnetic beads (Cell Signalling) in lysis buffer and rotated head over tail overnight at 4 °C. The beads were washed three times for 15 min with lysis buffer, and immunoprecipitated proteins were eluted by incubation in 1× NuPAGE LDS buffer (Thermo Fisher) for 10 min at 70 °C. Eluted immunoprecipitated proteins were removed from the beads, and DTT was added to 10% final volume. Immunoprecipitated proteins and input samples were analyzed by Western blot after incubation for an additional 5 min at 95 °C. For western blot analysis, proteins were separated on a 8% SDS-PAGE gel and transferred to a nitrocellulose membrane (Bio-Rad). After blocking with 5% milk in 0.05% Tween in PBS for 1 h at room temperature, the membrane was incubated with primary antibody in blocking solution overnight at 4 °C. Primary antibodies used were mouse anti-Myc 1:2000 (#9E10, Enzo); mouse anti-HA 1:1000 (#16B12, COVANCE); mouse anti-Tubulin 1:2000 (#903401, Biolegend); mouse anti-Fl(2)d 1:500 (#9G2, DSHB), guinea pig anti-Mettl3 1:500 and rabbit anti-Mettl14 (Lence et al. 2016) 1:250 The membrane was washed three times in PBST for 15 min and incubated for 1 h at room temperature with secondary antibody in blocking solution. Protein bands were detected using SuperSignalWest Pico chemiluminescent substrate (Thermo Scientific).

For the co-immunoprecipitation assays, shown in other figures, the following modifications were made:Cells were harvested 72 h after transfection and washed once with DPBS. The cell pellet was lysed in 0.5 ml of NET buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% Triton and 1 mM EDTA pH 8.0 supplemented with protease inhibitor and 10% glycerol) and sonicated for 3 cycles of 30 s at high power setting followed by incubation with RNase A at ice for 30 min Lysate was centrifuged at 15,000 × g for 10 min at 4 °C. Ten percent of the samples were taken out as input samples and rest were incubated with GFP-magnetic beads on head to toe rotary mixer at 4 °C. The beads were washed three times for 15 min with NET buffer, and proteins were eluted by boiling the beads for 3 min at 95 °C in SDS-page loading dye supplemented with 100 mM DTT. Where applicable, depletion of indicated proteins was performed as described under “Cell culture, RNA interference and transfection”. Double amounts of constructs were transfected in several conditions, as indicated in corresponding figure legends.

Co-immunoprecipitation assay and western blot analysis of the human MACOM subunits

For co-immunoprecipitation assay of the human MACOM subunits, selected truncations of human MACOM components were cloned individually into pcDNA3-derived vectors with His₆-HA₃-mCherry- or His₆-FLAG₃-eGFP- tags. 0.25 mln. HEK293T cells were seeded into 2 ml media in 6-well plates, grown for ~24 h (reaching ~75% confluency) and transfected with corresponding plasmids, 1 µg each, using Xtreme^® transfection agent (Roche) at 1:3 ratio. Cells were washed with PBS and harvested ~48 h after transfection using 250 µl of the lysis buffer (20 mM Tris-HCl, pH 7.5, 150 mM KCl, 1 mM EDTA, 0.1% Tween20), supplemented with Roche protease inhibitor. The cells were then flash frozen in liquid nitrogen and stored at −80 °C.

Upon thawing, the cells were further lysed by sonication for 30 s (0.5 s on/2 s off) at 10% amplitude. 2 µg RNase A was added to rule out RNA-mediated interactions. Soluble fraction was separated by centrifugation at full speed for 15 min and incubated with ~18 µl of magnetic anti-FLAG M2 beads (Sigma) for 1 h. The beads were washed 3-4 times with the lysis buffer. The resultant beads were mixed directly with the SDS loading dye and loaded onto 4-20% SDS gels (Biorad). The gels were scanned for GFP and mCherry signals using Typhoon FLA 9500 filters of 473 nm and 532 nm, respectively.

Immunoprecipitation and ubiquitination analysis of MycGFP-Fl(2)d and MycGFP-Nito

S2R+ cells were transfected with either MycGFP-tagged Nito or Fl(2)d proteins as described above. Forty-eight hours post-transfection attached cells in the 10-cm cell culture dish were washed 2x with cold PBS on ice. Cells were lysed with 1 ml of modified RIPA lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0,1% Na-deoxycholate), supplemented with complete protease inhibitor cocktail, 5 mM beta-glycerophosphate, 5 mM NaF, 1 mM Na-orthovanadate, 10 mM N-ethylmaleimide. Cells were then collected and incubated for 10 min on ice and centrifuged 15 min at 16,000 × g at 4 °C. Supernatant was transferred to a new tube and protein concentration measured using Bradford. 1.5 mg of proteins was incubated with 20 µL of washed GFPTrap-A beads (Chromotec) for 1 h at 4 °C end-over-end mixing. Beads were collected by centrifugation (3000 rpm, 1 min) and the supernatant removed. Beads were washed 1× with dilution buffer (10 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.5 mM EDTA, 1× Protease Inhibitor (Sigma), 10 mM N-ethylmaleimide), 3× with stringent wash buffer (8 M Urea, 1% SDS in 1× PBS) and 1× with wash buffer (1% SDS in 1× PBS). Forty-microlitres of 2× LDS sample buffer (Invitrogen) supplemented with 1 mM DTT was added and beads were incubated for 10 min at 70 °C. Twenty-five percent of eluted proteins were analyzed by WB. Primary antibodies used were as follows: mouse anti-Myc 1:2000 (#9E10, Enzo) and mouse Ub antibody (P4D1, Santa Cruz).

The remaining 75% of eluted proteins were used for ubiquitinome and proteome analysis. Proteins were alkylated with 5.5 mM CAA for 30 min at RT in the dark, stained using the Colloidal Blue Staining Kit (Life Technologies) and digested in-gel using trypsin. Peptides were extracted from gel and desalted on reversed-phase C18 StageTips⁴⁷. Samples were then subjected to MS and peptide identification.

Stable isotope labelling by amino acids in cell culture (SILAC)

For SILAC experiments (ubiquitinome and proteome of Hakai depleted cells), S2R+ cells were grown in Schneider medium (Dundee Cell) supplemented with either heavy (Arg10, Lys8) or light amino acids (Arg0, Lys0) (Sigma) for 6–8 passages and successful incorporation was confirmed by LC–MS/MS.

Ubiquitylome and proteome analysis in S2R+ cells

Ubiquitylome and proteome analysis of control and Hakai depleted SILAC S2R+ cells or Fl(2)d/Vir depleted S2R+ cells was performed as described previously^43,48. Following modifications were made: S2R+ cells were grown in Schneider medium (Dundee Cell) supplemented with either heavy (Arg10, Lys8) or light amino acids (Arg0, Lys0) (Sigma) or without supplement for the label-free proteomes (Fl(2)d and Vir KD). Depletion of the different factors was performed with corresponding double-stranded RNA three times during 6 days and scaled up to obtain 50 mg of proteins per replicate (8–10, 15-cm cell culture dishes). Six hours prior to cell lysis, the MG132 proteasome inhibitor was added to a final concentration of 15 μM. Cells were lysed in modified RIPA lysis buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.1% Na-deoxycholate) supplemented with complete protease inhibitor cocktail (Roche), 5 mM -glycerophosphate, 5 mM NaF, 1 mM Na-orthovanadate, 10 mM N-ethylmaleimide. 1.5 ml of buffer was used per each 15-cm dish. All lysates of the same transfection were combined in a falcon and protein concentrations were measured by Bradford. Hundred micrograms of each protein sample was collected for WB analysis. For ubiquitylome and proteome analysis 25 mg of heavy and 25 mg of light labelled protein lysates were joined in a 1:1 ratio as follows: for forward experiment heavy labelled lysates with Hakai KD and light labelled lysates with control KD were joined, and vice versa for reverse experiment. 50 μg were then collected for proteome analysis. Finally, ice-cold acetone was added to 80% final conc. (4xV) and precipitated O/N at −20 °C and subjected to MS.

Label-free proteomes

A total of 15 × 10⁶ S2R+ cells were transfected with Myc-GFP-tagged HAKAI-long isoform in a 10-cm cell culture dish. In parallel, cells were transfected with Myc-GFP as negative control. After 72 h, the cells were harvested and washed with cold PBS. Cells were lysed with 1 ml of NET buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl, 0.1% Triton and 1 mM EDTA pH 8.0) and supplemented with 10% Glycerol and Protease inhibitor cocktail (Roche). Lysates were sonicated for 3 cycles of 30 s at a high power setting followed by incubation with RNAse A on ice for 30 min Lysate was centrifuged at 15,000 × g for 10 min at 4 °C. The cleared lysates were incubated with GFP-magnetic beads on a head-to-toe rotary mixer at 4 °C for 2 h. The beads were washed three times for 15 min with NET buffer, and proteins were eluted by incubating at 70 °C in NuPAGE buffer.

Proteome and ubiquitylome analyses

MS sample preparation, proteome analysis, MS, and peptide identification were performed as described previously in ref. ⁴⁸. For peptide identification in SILAC samples, raw data files were analyzed using MaxQuant (development version 1.5.2.8) to calculate the ratios between the different conditions⁴⁹. For the MaxQuant analysis, we used different parameter groups to define group-specific parameters to invert the SILAC ratios in replicate 2 (Reverse). As result of these settings H/L in both experiments represents HAKAI KD/Non-targeting control. The data with all quantified ubiquitylation sites (di-glycine sites) and protein groups are provided as Supplementary_Data_3 (ubiquitylome analysis) and Supplementary_Data 4 (proteome analysis).

Analysis of label-free samples was performed using default setting for the LFQ analysis in MaxQuant (1.5.2.8) and the Perseus software version 1.5.6.0 to perform calculation of p value and Student’s t test⁵⁰. Parent ion and MS2 spectra were searched against a database containing D. melanogaster protein sequences obtained from the UniProtKB released in May 2016 using Andromeda search engine⁵¹.

Yeast-two-hybrid assay (Y2H)

Yeast-two-hybrid assay was performed using S. cerevisiae yeast strain [trp1-901, leu2-3,112, ura3-52, his3-200, gal4Δ, gal80Δ, LYS2::GAL1-HIS3, GAL2-ADE2, met2::GAL7-lacZ]. cDNAs of all tested genes (Mettl3, Mettl14, Fl(2)d, Vir, Nito, Flacc, Hakai) were cloned in vectors pGAD424-GW and pGBT9-GW, with Leu2 and Trp1 markers (kindly provided by Helle Ulrich Lab, IMB Mainz) to express all candidates with either the C-terminal Gal4-activation domain or the C-terminal Gal4-DNA binding domain, respectively. Briefly, yeast cells were grown in YPD medium until they reached OD = 0.6. Cells were centrifuged at 3500 rpm for 7 min at RT and washed 1× with water, 1× with 250 ml of SORB (100 mM LiOAc, 10 mM Tris pH 8.0, 1 mM EDTA pH 8.0, 1 M Sorbitol) and 1× with 100 ml of SORB. Pellets were resuspended in 3.6 ml of SORB and 400 ml of ssDNA carrier was added to competent cells. Fifty microlitres aliquots of cells were mixed with 100 ng of plasmid DNA. 6× volumes of PEG solution (10 mM Tris pH 8.0, 1 mM EDTA pH 8.0, 40 (w/v)-% PEG 3350) were then added to the cell-DNA mixture that was further incubated at RT for 30 min Next, 1/9 of DMSO were added to cells that were subjected to 15 min heat shock at 42 °C. Following 2 min centrifugation at 1968 × g and RT, the cell pellet was resuspended in 500 μL of water and 100 μL of cell solution was plated onto Trp-/Leu- selection agar plates. After 3 days of incubation at 30 °C, 5 colonies of each transformation were resuspended in 500 μL of water and 4 μL were spotted on selection agar plates (Trp-/Leu- and Trp-/Leu-/His-). Plates were imaged in a 24-h interval.

RNA-seq analysis

Raw data processing, differential expression analysis and splicing analysis was done as described in ref. ²⁴. All samples from GSE105900 as well as the Hakai sample from GSE158663 were processed at the same time with the same tools and tool versions. The controls used as a reference for the differential splicing and the differential expression analysis are the same. In short the libraries were sequenced on a NextSeq500 with a read length of 85 bp single read and converted to fastq using bcl2fastq (v.2.19) and mapped against Ensembl release 90 of D. melanogaster using STAR (⁵², v. 2.5.10)). Counts per gene were derived using featureCounts (⁵³, v. 2.5.1), Differential expression analysis was performed using Bioconductor/DESeq2 (⁵⁴, v1.16.1)) and filtered for an FDR < 5%, default independent filtering was used. Differential splicing analysis was performed using rMATS (⁵⁵, v. 3.2.5) and filtered for an FDR < 10%.

Statistics

For m⁶A level measurements datasets were compared using two-tailed Student’s t test for unequal variances. Fl(2)d levels upon Control, Metll3, Nito, Vir, Flacc and Hakai KD were compared using two-tailed Student’s t test for equal variances. Normality was verified and homogeneity of variances was analyzed with Levene’s test. Detailed descriptions of confidence intervals, effect sizes, degrees of freedom are shown in the Source data. Statistical tests used for RNAseq data analysis and mass spectrometry analysis are described in detail under relevant sections of “Methods” part.

Reporting summary

Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

All data needed to evaluate the conclusions in the paper are present in the paper and/or Supplementary Materials. Additional data related to this paper may be requested from the authors. RNA-seq data are available in GEO: GSE158663. Proteomics data are available in PRIDE: PXD022294. Source data are provided with this paper.

References

Roignant J. Y., Soller M. m⁶A in mRNA: an ancient mechanism for fine-tuning gene expression. Trends Genet. 33, 380–390 (2017).
Shi, H., Wei, J. & He, C. Where, when, and how: context-dependent functions of RNA methylation writers, readers, and erasers. Mol. Cell 74, 640–650 (2019).
Article CAS PubMed PubMed Central Google Scholar
Zaccara, S., Ries, R. J. & Jaffrey, S. R. Reading, writing and erasing mRNA methylation. Nat. Rev. Mol. Cell Biol. 20, 608–624 (2019).
Article CAS PubMed Google Scholar
Anreiter I., Mir Q., Simpson J. T., Janga S. C., Soller M. New twists in detecting mRNA modification dynamics. Trends Biotechnol. 39, 72–89 (2020).
Batista, P. J. et al. m(⁶)A RNA modification controls cell fate transition in mammalian embryonic stem cells. Cell Stem Cell 15, 707–719 (2014).
Article CAS PubMed PubMed Central Google Scholar
Geula, S. et al. Stem cells. m⁶A mRNA methylation facilitates resolution of naive pluripotency toward differentiation. Science 347, 1002–1006 (2015).
Article CAS PubMed ADS Google Scholar
Morena F., Argentati C., Bazzucchi M., Emiliani C., Martino S. Above the epitranscriptome: RNA modifications and stem cell identity. Genes 9, 329 (2018).
Malla, S., Melguizo-Sanchis, D. & Aguilo, F. Steering pluripotency and differentiation with N(6)-methyladenosine RNA modification. Biochim Biophys. Acta Gene Regul. Mech. 1862, 394–402 (2019).
Article CAS PubMed Google Scholar
Xiang, Y. et al. RNA m(⁶)A methylation regulates the ultraviolet-induced DNA damage response. Nature 543, 573–576 (2017).
Article CAS PubMed PubMed Central ADS Google Scholar
Fustin, J. M. et al. RNA-methylation-dependent RNA processing controls the speed of the circadian clock. Cell 155, 793–806 (2013).
Article CAS PubMed Google Scholar
Wang, C. Y., Yeh, J. K., Shie, S. S., Hsieh, I. C. & Wen, M. S. Circadian rhythm of RNA N6-methyladenosine and the role of cryptochrome. Biochem Biophys. Res Commun. 465, 88–94 (2015).
Article CAS PubMed Google Scholar
Fustin, J. M. et al. Two Ck1delta transcripts regulated by m⁶A methylation code for two antagonistic kinases in the control of the circadian clock. Proc. Natl Acad. Sci. USA 115, 5980–5985 (2018).
Article PubMed PubMed Central Google Scholar
Livneh, I., Moshitch-Moshkovitz, S., Amariglio, N., Rechavi, G. & Dominissini, D. The m(⁶)A epitranscriptome: transcriptome plasticity in brain development and function. Nat. Rev. Neurosci. 21, 36–51 (2020).
Article CAS PubMed Google Scholar
Haussmann, I. U. et al. m⁶A potentiates Sxl alternative pre-mRNA splicing for robust Drosophila sex determination. Nature 540, 301–304 (2016).
Article CAS PubMed ADS Google Scholar
Lence, T. et al. m⁶A modulates neuronal functions and sex determination in Drosophila. Nature 540, 242–247 (2016).
Article CAS PubMed ADS Google Scholar
Kan, L. et al. The m(⁶)A pathway facilitates sex determination in Drosophila. Nat. Commun. 8, 15737 (2017).
Article CAS PubMed PubMed Central ADS Google Scholar
Zhong H., Tang H. F., Kai Y. N6-methyladenine RNA modification (m⁶A): an emerging regulator of metabolic diseases. Curr. Drug Targets 21, 1056–1067 (2020).
Angelova, M. T. et al. The emerging field of epitranscriptomics in neurodevelopmental and neuronal disorders. Front. Bioeng. Biotechnol. 6, 46 (2018).
Article PubMed PubMed Central Google Scholar
Han, B. & Yao, H. H. N(6)-methyladenosine as a novel regulator of brain physiology and diseases. Curr. Med. Sci. 40, 401–406 (2020).
Article CAS PubMed Google Scholar
Chen, X. Y., Zhang, J. & Zhu, J. S. The role of m(6)A RNA methylation in human cancer. Mol. Cancer 18, 103 (2019).
Article PubMed PubMed Central Google Scholar
He, L. et al. Functions of N6-methyladenosine and its role in cancer. Mol. Cancer 18, 176 (2019).
Article PubMed PubMed Central Google Scholar
Wang, T., Kong, S., Tao, M. & Ju, S. The potential role of RNA N6-methyladenosine in Cancer progression. Mol. Cancer 19, 88 (2020).
Article CAS PubMed PubMed Central Google Scholar
Knuckles P., Buhler M. Adenosine methylation as a molecular imprint defining the fate of RNA. FEBS Lett. 592, 2845–2859 (2018).
Knuckles, P. et al. Zc3h13/Flacc is required for adenosine methylation by bridging the mRNA-binding factor Rbm15/Spenito to the m(6)A machinery component Wtap/Fl(2)d. Genes Dev. 32, 415–429 (2018).
Article CAS PubMed PubMed Central Google Scholar
Balacco, D. L. & Soller, M. The m(6)A writer: rise of a machine for growing tasks. Biochemistry 58, 363–378 (2019).
Article CAS PubMed Google Scholar
Ruzicka, K. et al. Identification of factors required for m(6) A mRNA methylation in Arabidopsis reveals a role for the conserved E3 ubiquitin ligase HAKAI. N. Phytol. 215, 157–172 (2017).
Article CAS Google Scholar
Yue, Y. et al. VIRMA mediates preferential m(6)A mRNA methylation in 3’UTR and near stop codon and associates with alternative polyadenylation. Cell Discov. 4, 10 (2018).
Article PubMed PubMed Central CAS Google Scholar
Sledz P., Jinek M. Structural insights into the molecular mechanism of the m(6)A writer complex. Elife 5, e18434 (2016).
Wang, P., Doxtader, K. A. & Nam, Y. Structural basis for cooperative function of Mettl3 and Mettl14 methyltransferases. Mol. Cell 63, 306–317 (2016).
Article CAS PubMed PubMed Central Google Scholar
Wang, X. et al. Structural basis of N(6)-adenosine methylation by the METTL3-METTL14 complex. Nature 534, 575–578 (2016).
Article CAS PubMed ADS Google Scholar
Ping, X. L. et al. Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase. Cell Res. 24, 177–189 (2014).
Article CAS PubMed PubMed Central Google Scholar
Patil, D. P. et al. m⁶A RNA methylation promotes XIST-mediated transcriptional repression. Nature 537, 369–373 (2016).
Article CAS PubMed PubMed Central ADS Google Scholar
Guo, J., Tang, H. W., Li, J., Perrimon, N. & Yan, D. Xio is a component of the Drosophila sex determination pathway and RNA N(6)-methyladenosine methyltransferase complex. Proc. Natl Acad. Sci. USA 115, 3674–3679 (2018).
Article CAS PubMed PubMed Central Google Scholar
Wen, J. et al. Zc3h13 regulates nuclear RNA m(6)A Methylation and Mouse Embryonic Stem Cell Self-Renewal. Mol. Cell 69, 1028–1038 e1026 (2018).
Article CAS PubMed PubMed Central Google Scholar
Fujita, Y. et al. Hakai, a c-Cbl-like protein, ubiquitinates and induces endocytosis of the E-cadherin complex. Nat. Cell Biol. 4, 222–231 (2002).
Article CAS PubMed Google Scholar
Figueroa, A., Fujita, Y. & Gorospe, M. Hacking RNA: Hakai promotes tumorigenesis by enhancing the RNA-binding function of PSF. Cell Cycle 8, 3648–3651 (2009).
Article CAS PubMed Google Scholar
Aparicio, L. A., Valladares, M., Blanco, M., Alonso, G. & Figueroa, A. Biological influence of Hakai in cancer: a 10-year review. Cancer Metastasis Rev. 31, 375–386 (2012).
Article CAS PubMed PubMed Central Google Scholar
Horiuchi, K. et al. Identification of Wilms’ tumor 1-associating protein complex and its role in alternative splicing and the cell cycle. J. Biol. Chem. 288, 33292–33302 (2013).
Article CAS PubMed PubMed Central Google Scholar
Wan, C. et al. Panorama of ancient metazoan macromolecular complexes. Nature 525, 339–344 (2015).
Article CAS PubMed PubMed Central ADS Google Scholar
Mukherjee, M. et al. Structure of a novel phosphotyrosine-binding domain in Hakai that targets E-cadherin. EMBO J. 31, 1308–1319 (2012).
Article CAS PubMed PubMed Central Google Scholar
Schutt, C. & Nothiger, R. Structure, function and evolution of sex-determining systems in Dipteran insects. Development 127, 667–677 (2000).
Article CAS PubMed Google Scholar
Kaido, M., Wada, H., Shindo, M. & Hayashi, S. Essential requirement for RING finger E3 ubiquitin ligase Hakai in early embryonic development of Drosophila. Genes Cells 14, 1067–1077 (2009).
Article CAS PubMed Google Scholar
Schunter, S. et al. Ubiquitylation of the acetyltransferase MOF in Drosophila melanogaster. PLoS ONE12, e0177408 (2017).
Article PubMed PubMed Central CAS Google Scholar
Bokar, J. A., Rath-Shambaugh, M. E., Ludwiczak, R., Narayan, P. & Rottman, F. Characterization and partial purification of mRNA N6-adenosine methyltransferase from HeLa cell nuclei. Internal mRNA methylation requires a multisubunit complex. J. Biol. Chem. 269, 17697–17704 (1994).
Article CAS PubMed Google Scholar
Juszkiewicz, S. & Hegde, R. S. Quality control of orphaned proteins. Mol. Cell 71, 443–457 (2018).
Article CAS PubMed PubMed Central Google Scholar
Kondo, S. & Ueda, R. Highly improved gene targeting by germline-specific Cas9 expression in Drosophila. Genetics 195, 715–721 (2013).
Article CAS PubMed PubMed Central Google Scholar
Rappsilber, J., Mann, M. & Ishihama, Y. Protocol for micro-purification, enrichment, pre-fractionation and storage of peptides for proteomics using StageTips. Nat. Protoc. 2, 1896–1906 (2007).
Article CAS PubMed Google Scholar
Heidelberger J. B. et al. Proteomic profiling of VCP substrates links VCP to K6-linked ubiquitylation and c-Myc function. EMBO Rep. 19, e44754 (2018).
Cox, J. & Mann, M. MaxQuant enables high peptide identification rates, individualized p.p.b. -range mass accuracies and proteome-wide protein quantification. Nat. Biotechnol. 26, 1367–1372 (2008).
Article CAS PubMed Google Scholar
Tyanova, S. et al. The Perseus computational platform for comprehensive analysis of (prote)omics data. Nat. Methods 13, 731–740 (2016).
Article CAS PubMed Google Scholar
Cox, J. et al. Andromeda: a peptide search engine integrated into the MaxQuant environment. J. Proteome Res 10, 1794–1805 (2011).
Article CAS PubMed ADS Google Scholar
Dobin, A. et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics 29, 15–21 (2013).
Article CAS PubMed Google Scholar
Liao, Y., Smyth, G. K. & Shi, W. The Subread aligner: fast, accurate and scalable read mapping by seed-and-vote. Nucleic Acids Res. 41, e108 (2013).
Article PubMed PubMed Central CAS Google Scholar
Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 15, 550 (2014).
Article PubMed PubMed Central CAS Google Scholar
Shen, S. et al. rMATS: robust and flexible detection of differential alternative splicing from replicate RNA-Seq data. Proc. Natl Acad. Sci. USA 111, E5593–5601 (2014).
Article CAS PubMed PubMed Central Google Scholar

Download references

Acknowledgements

We thank the Bloomington, Kyoto and Vienna stock Center for fly lines and the Drosophila Genomics Resource Center at Indiana University for plasmids and cell lines. We are indebted to S. Hayashi for his effort to recover the Hakai¹ allele as well as BestGene and the University of Cambridge Department of Genetics Fly Facility for injections. We thank members of the Roignant and Soller lab for helpful discussion. We thank Christian Renz from the Ulrich group at IMB for sharing reagents and advices for the yeast-two-hybrid assay and Catia Igreja and Heike Budde from late Elisa Izaurralde lab for sharing plasmids used in this study. We thank the IMB Genomics core facility for their helpful support and the use of its NextSeq500 (INST 247/870-1 FUGG). Research in the laboratory of J.-Y.R. is supported by University of Lausanne, the Swiss National Science Foundation (310030_197906), the Deutsche Forschungsgemeinschaft RO 4681/9-1, RO 4681/12-1 and RO 4681/13-1. M.S. is funded by the BBSRC (BB/R002932/1) and the Leverhulme Trust. Research in the M.J. laboratory is supported by the Swiss National Competence Center for Research (NCCR) RNA & Disease. M.K. is supported by EMBO (ALTF 1087-2018) and Human Frontier Science Program (LT000248 2019-L) postdoctoral fellowships. M.J. is an International Research Scholar of the Howard Hughes Medical Institute and Vallee Scholar of the Bert L & N Kuggie Vallee Foundation. P.Beli is supported by the Emmy Noether Program (BE 5342/1-1 and BE 5342/1-2). C.P. in the lab of J.-Y.R. is supported by a Boehringer Ingelheim Fonds fellowship.

Author information

Tina Lence
Present address: Institute for Molecular Infection Biology (IMIB), Faculty of Medicine, University of Würzburg, Würzburg, Germany
These authors contributed equally: Praveen Bawankar, Tina Lence, Chiara Paolantoni.

Authors and Affiliations

Institute of Pharmaceutical and Biomedical Sciences, Johannes Gutenberg-University Mainz, Mainz, Germany
Praveen Bawankar, Dominik Jacob, Florian M. Richter, Mark Helm & Jean-Yves Roignant
Institute of Molecular Biology (IMB), Mainz, Germany
Tina Lence, Jan B. Heidelberger, Violeta Morin & Petra Beli
Center for Integrative Genomics, Génopode Building, Faculty of Biology and Medicine, University of Lausanne, Lausanne, Switzerland
Chiara Paolantoni & Jean-Yves Roignant
School of Biosciences, College of Life and Environmental Sciences, University of Birmingham, Birmingham, UK
Irmgard U. Haussmann, Mohanakarthik P. Nallasivan & Matthias Soller
Department of Life Science, Faculty of Health, Education and Life Sciences, Birmingham City University, Birmingham, UK
Irmgard U. Haussmann
Department of Biochemistry, University of Zurich, Zurich, Switzerland
Migle Kazlauskiene & Martin Jinek
Bioinformatics core facility, Institute of Molecular Biology (IMB), Mainz, Germany
Nastasja Kreim
Institute of Developmental Biology and Neurobiology (IDN), Johannes Gutenberg-Universität, Mainz, Germany
Petra Beli
Birmingham Centre for Genome Biology, University of Birmingham, Birmingham, UK
Matthias Soller

Authors

Praveen Bawankar
View author publications
You can also search for this author in PubMed Google Scholar
Tina Lence
View author publications
You can also search for this author in PubMed Google Scholar
Chiara Paolantoni
View author publications
You can also search for this author in PubMed Google Scholar
Irmgard U. Haussmann
View author publications
You can also search for this author in PubMed Google Scholar
Migle Kazlauskiene
View author publications
You can also search for this author in PubMed Google Scholar
Dominik Jacob
View author publications
You can also search for this author in PubMed Google Scholar
Jan B. Heidelberger
View author publications
You can also search for this author in PubMed Google Scholar
Florian M. Richter
View author publications
You can also search for this author in PubMed Google Scholar
Mohanakarthik P. Nallasivan
View author publications
You can also search for this author in PubMed Google Scholar
Violeta Morin
View author publications
You can also search for this author in PubMed Google Scholar
Nastasja Kreim
View author publications
You can also search for this author in PubMed Google Scholar
Petra Beli
View author publications
You can also search for this author in PubMed Google Scholar
Mark Helm
View author publications
You can also search for this author in PubMed Google Scholar
Martin Jinek
View author publications
You can also search for this author in PubMed Google Scholar
Matthias Soller
View author publications
You can also search for this author in PubMed Google Scholar
Jean-Yves Roignant
View author publications
You can also search for this author in PubMed Google Scholar

Contributions

P. Bawankar, T.L., C.P. M.S. and J.-Y.R. conceived the project. P. Bawankar, T.L., C.P. contributed equally and are listed in the alphabetical order. All authors contributed to the experimental design, analysis, and interpretation of results. Experimental contributions were as follows: T.L. initiated the work, which was taken over by P. Bawankar and C.P. They performed all experiments except the following ones: I.U.H., M.P.N. and M.S. performed molecular biology, immunostaining of polytene chromosomes and genetic experiments. M.K. performed the HEK293T co-immunoprecipitation assays with help from M.J. J.B.H. and P. Beli performed MS-based proteomics for ubiquitylome, Hakai interactomes and proteome analysis. D.J., F.M.R. carried out mass spectrometry measurement with the help of M.H. N.K. carried out the bioinformatic analysis. V.M. helped with the generation of Hakai mutants. P. Bawankar, T.L., C.P., M.S. and J.-Y.R. wrote the paper with input from all the other authors.

Corresponding authors

Correspondence to Matthias Soller or Jean-Yves Roignant.

Ethics declarations

Competing interests

The authors declare no competing interests

Additional information

Peer review information Nature Communications thanks the anonymous reviewers for their contribution to the peer review of this work. Peer reviewer reports are available.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Supplementary Information

Peer Review File

Description of Additional Supplementary Files

Supplementary Data 1

Supplementary Data 2

Supplementary Data 3

Supplementary Data 4

Supplementary Data 5

Reporting Summary

Source data

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Cite this article

Bawankar, P., Lence, T., Paolantoni, C. et al. Hakai is required for stabilization of core components of the m⁶A mRNA methylation machinery. Nat Commun 12, 3778 (2021). https://doi.org/10.1038/s41467-021-23892-5

Download citation

Received: 21 October 2020
Accepted: 17 May 2021
Published: 18 June 2021
DOI: https://doi.org/10.1038/s41467-021-23892-5

This article is cited by

Intrafamily heterooligomerization as an emerging mechanism of methyltransferase regulation
- Haley V. Hobble
- Christine E. Schaner Tooley
Epigenetics & Chromatin (2024)
RNA modifications in physiology and disease: towards clinical applications
- Sylvain Delaunay
- Mark Helm
- Michaela Frye
Nature Reviews Genetics (2024)
New horizons for the role of RNA N6-methyladenosine modification in hepatocellular carcinoma
- Yu-jia Li
- Yang-ling Qiu
- Shi-zhong Zheng
Acta Pharmacologica Sinica (2024)
Role of m6A RNA Methylation in Ischemic Stroke
- Yayun Xu
- Wenqiang Liu
- Lijie Ren
Molecular Neurobiology (2024)
m6A modification of plant virus enables host recognition by NMD factors in plants
- Hao He
- Linhao Ge
- Fangfang Li
Science China Life Sciences (2024)

Comments

By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.